MedTrace Logo

Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D

NCT01166763 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-07-18

Study results available
· View outcomes & findings →

Summary

The overall goal of this project is to determine if high dose vitamin D3 given to premenopausal women at high risk for development of breast cancer, who initially have insufficient levels of 25-hydroxy vitamin D (\<30 ng/ml), will raise 25(OH)D levels above 50 ng/ml. If so, will certain risk biomarkers for development of breast cancer be reliably and favorably modulated?

Conditions

Interventions

DRUG

vitamin D3

oral capsules, 10,000 IU per week for 6 months

Sponsors & Collaborators

  • BTR Group

    collaborator INDUSTRY

  • Carol Fabian, MD

    lead OTHER

Principal Investigators

  • Carol Fabian, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01166763 on ClinicalTrials.gov